Companion Society Meetings
Renal Pathology Society
Ancillary Testing in Renal Pathology
Sunday, March 18, 2018, 8:30 AM - 12:00 PM
3 CME and 2.5 SAMs
Alton Brad Farris, MD, Emory University, Atlanta, GA
Kammi J. Henriksen, MD, University of Chicago, Chicago, IL
The 2018 Renal Pathology Society Companion meeting will focus on updating and introducing new ancillary testing modalities within the field of renal pathology. These topics demonstrate a broad range of diagnostic techniques including the usefulness of immunofluorescence staining for IgG subtypes in renal biopsies, staining for collagen chains in Alport syndrome and introducing a novel immunohistochemical marker for fibrillary glomerulonephritis. In addition, the molecular diagnosis of antibody-mediated rejection in kidney allografts will be addressed as will the use of digital pathology in the diagnosis of renal disease.
Upon completion of this educational activity, the learner will be able to:
- Understand the utility of IgG subclass staining and identify clinical scenarios in which pursuing this testing is appropriate
- Understand the role and limitations in interpreting collagen chain staining in the diagnosis of Alport syndrome
- Identify the differential diagnosis of glomerular disease with fibrillary deposits and develop a diagnostic algorithm to determine the correct diagnosis
- Understand the current diagnostic criteria for antibody-mediated rejection in kidney allografts and the current role and limitations of C4d staining
- Help identify future roles for digital technology in the field of medical renal pathology
|8:30 AM||The Utility of IgG Subclass Staining in Renal Biopsies
Jessica Hemminger, MD, Ohio State University, Columbus, OH
|9:10 AM||The Role of Immunofluorescence Staining for Collagen Chains in the Diagnosis of Alport Syndrome
Samih Nasr, MD, Mayo Clinic, Rochester, MN
|9:50 AM||DNAJB9 - A Novel Diagnostic Marker for Fibrillary Glomerulonephritis
Mariam Priya Alexander, MD, Mayo Clinic, Rochester, MN
|10:45 AM||The Molecular Diagnosis of AMR and the Role of C4d
Michael Mengel, MD, University of Alberta, Calgary, AB, Canada
|11:25 AM||Digital Nephropathology in Clinical Practice, Trials and Research
Laura Barisoni, MD, University of Miami, Miami, FL
Continuing Medical Education and Maintenance of Certification
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The United States and Canadian Academy of Pathology and Renal Pathology Society. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of
3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 2.5 SAM credit hours.